fx-322 hearing loss treatment

Frequency Therapeutics Provides Business Updates and Q3 2022 Financial Results

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022. “This past quarter has been one of momentum and execution. With the completion of…

Read More
fx-322 phase 2b hearing loss study

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142…

Read More
frequency therapeutics fhh conference

Frequency Therapeutics Sponsors Student Education Grant for Future of Hearing Healthcare Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, will provide student sponsorship for a second year to the Future of Hearing Healthcare Conference, which will allow up to 75 audiology graduate students to attend…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics FX-322-113 Study with Severe Sensorineural Hearing Loss Finds Speech Perception Improvements in Noise

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss (SNHL). In the study, FX-322…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Provides Business Updates and Q3 2021 Financial Results

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, has announced business updates and financial results for the third quarter ended September 30, 2021. “Frequency has made significant operational progress throughout this year, highlighted by the initiation…

Read More
fx-322 phase 2b hearing loss study

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Study and FDA Agreement on Speech Perception as Primary Endpoint

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that the first subject has been dosed in a new FX-322 Phase 2b study (FX-322-208) being conducted in a refined population of individuals with sensorineural hearing…

Read More
fx-322 hearing improvement later time

Frequency Therapeutics Announces New FX-322 Results Showing Additional Study Participants Gain Hearing Improvements at Later Time Points

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore human function, has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Expands Clinical Development Team with Appointment of Jeffery T. Lichtenhan, Ph.D.

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed…

Read More
frequency therapeutics student grant

Frequency Therapeutics Sponsors Student Education at Future of Hearing Healthcare Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced its sponsorship of the Future of Hearing Healthcare Conference, which will allow 55 audiology graduate students to attend the event at no cost. The…

Read More